2 High-Yield Dividend Stocks to Buy in August and Hold for a Decade or Longer
These high-yield dividend stocks are built to last.
The Zacks Analyst Blog Highlights Amazon.com, Salesforce, Abbott Laboratories and Fossil Group
Amazon, Salesforce, Abbott and Fossil Group show diverging trends as AI spending weighs on margins, healthcare pipelines expand, and retail turnarounds gain traction.
Abbott Gains in Nutrition With Adult Segment Leading Growth
ABT Nutrition unit posts steady gains as adult-focused brands like Ensure and Glucerna drive global demand and market share growth.
If You'd Invested $1,000 in AbbVie Stock 10 Years Ago, Here's How Much You'd Have Today
You'd be sitting pretty right now.
2 Stocks to Buy on the Dip and Hold for 10 Years
There should be plenty of long-term upside for these stocks for investors willing to ride out the storm.
Looking Into Abbott Laboratories's Recent Short Interest - Abbott Laboratories ( NYSE:ABT )
Abbott Laboratories's ABT short percent of float has fallen 3.64% since its last report. The company recently reported that it has 18.33 million shares sold short, which is 1.06% of all regular shares that are available for trading.
Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data
TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.
3 Dividend Stocks to Double Up On Right Now
These stocks offer great dividends and more.
Abbott Taps Growing TMVR Market With Tendyne System
ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.
Recent Filing Shows That Rep. Josh Gottheimer Sold Over $6K Worth of Abbott Laboratories Stock - Abbott Laboratories ( NYSE:ABT )
A August filing shows that Representative Josh Gottheimer reported a sale in Abbott Laboratories ABT, valued between $6,006 and $90,000. The transaction date is listed as July 18, 2025, with the report published on August 11, 2025. At present, Abbott Laboratories shares are trading down 1.0% at ...
3 Stocks Retirees Should Absolutely Love
These stocks check off all the boxes for investors no longer receiving a paycheck.
Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock
Abbott outpaces market trends as EPD sales surge, fueled by double-digit growth, biosimilar approvals and strong product demand.
Gauzy Ltd. Announces Board of Directors Changes Following Annual Meeting
Gauzy Pleased to Announce Alejandro Weinstein, Former Director in Gauzy, Elected to Board. A Long-Time Investor and Shareholder Engaged with the Company Since ...
Gauzy Ltd. Announces Board of Directors Changes Following Annual Meeting - Gauzy ( NASDAQ:GAUZ )
Gauzy Pleased to Announce Alejandro Weinstein, Former Director in Gauzy, Elected to Board; A Long-Time Investor and Shareholder Engaged with the Company Since 2016 Gauzy Adopts Leaner Board to Reduce Corporate Expenses and Maintain Agility TEL AVIV, Israel, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- ...
Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?
ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.
Reckitt Benckiser Group PLC Investors: Please contact the Portnoy Law Firm to recover your losses. August 4, 2025 Deadline to file Lead Plaintiff Motion - Reckitt Benckiser Group ( OTC:RBGLY )
Investors can contact the law firm at no cost to learn more about recovering their losses
If You'd Invested $1,000 in AbbVie ( ABBV ) Stock 10 Years Ago, Here's How Much You'd Have Today
Spoiler: You would have done well -- and even better if you'd reinvested your dividends.
3 Unstoppable Stocks to Buy in August
Here are hot stocks to buy in a hot month.
2 Top Stocks to Buy Now If You Want Decades of Passive Income
These companies have provided strong returns to long-term shareholders, but they aren't done yet.
Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever
Being a great investor doesn't have to be complicated or expensive.
Former U.S. Attorney Rick Mountcastle Joins Guttman Buschner PLLC and Co-Produces Explosive Nursing Home Docuseries Premiering August 1 on Amazon
WASHINGTON, July 29, 2025 /PRNewswire/ -- Guttman Buschner PLLC is pleased to announce that former United States Attorney Rick Mountcastle has joined the firm as Of Counsel, bringing his decades of nationally recognized litigation and enforcement experience to the firm's robust whistleblower and ...
Glucose Health, Inc. ( OTC: GLUC ) Highlights U.S. Department of Health and Human Services Designation of Key Nutrient Validating Company's Patent-Pending Nutrition Formulation via CNBC, Fox Business and Bloomberg Television Media Blitz
BENTONVILLE, Ark., July 29, 2025 ( GLOBE NEWSWIRE ) -- Glucose Health, Inc. ( OTC: GLUC ) , a publicly traded consumer healthcare company focused on diabetic nutrition and soluble fiber-based nutrition formulations, today announced the launch of a targeted media blitz to bring greater awareness ...
Glucose Health, Inc. ( OTC: GLUC ) Highlights U.S. Department of Health and Human Services Designation of Key Nutrient Validating Company's Patent-Pending Nutrition Formulation via CNBC, Fox Business and Bloomberg Television Media Blitz - Glucose Health ( OTC:GLUC )
BENTONVILLE, Ark., July 29, 2025 ( GLOBE NEWSWIRE ) -- Glucose Health, Inc.
RECKITT ( RBGLY ) DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Reckitt Benckiser Group plc and Encourages Investors to Contact the Firm - Reckitt Benckiser Group ( OTC:RBGLY )
NEW YORK, July 28, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Reckitt Benckiser Group plc ( "Reckitt" or the "Company" ) RBGLY in the United States District Court for ...
Reckitt Benckiser Group PLC Investors: Please contact the Portnoy Law Firm to recover your losses; August 4, 2025 Deadline to file Lead Plaintiff Motion - Reckitt Benckiser Group ( OTC:RBGLY )
Investors can contact the law firm at no cost to learn more about recovering their losses
Scott+Scott Attorneys at Law LLP Again Alerts Investors of The Pending Securities Class Action Against Reckitt Benckiser Group PLC ( OTC: RBGLY ) - Reckitt Benckiser Group ( OTC:RBGLY )
NEW YORK, July 28, 2025 ( GLOBE NEWSWIRE ) -- Scott+Scott Attorneys at Law LLP ( "Scott+Scott" ) , an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Southern District of New York against ...
5 Dividend Stocks to Hold for the Next 20 Years
Discover five unstoppable dividend stocks that could pay you for life, and why I wouldn't sell any of them!
HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View
HCA Healthcare's Q2 earnings rose 24% year over year on stronger patient volumes. EPS for 2025 is expected to be within $25.5-$27, up from the earlier view of $24.05-$25.85.
The Zacks Analyst Blog Highlights Wells Fargo, Abbott Laboratories, American Express, TSS and Maui Land & Pineapple
Wells Fargo, Abbott, and American Express lead Zacks highlights, while TSS surges on AI growth and MLP eyes land monetization.
Reckitt Benckiser Group PLC Investors: Please contact the Portnoy Law Firm to recover your losses. August 4, 2025 Deadline to file Lead Plaintiff Motion. - Reckitt Benckiser Group ( OTC:RBGLY )
Investors can contact the law firm at no cost to learn more about recovering their losses
Scott+Scott Attorneys at Law LLP Again Alerts Investors of The Pending Class Action Against Reckitt Benckiser Group PLC ( OTC: RBGLY ) - Reckitt Benckiser Group ( OTC:RBGLY )
NEW YORK, July 23, 2025 ( GLOBE NEWSWIRE ) -- Scott+Scott Attorneys at Law LLP ( "Scott+Scott" ) , an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Southern District of New York against ...
Reckitt Benckiser Group PLC Investors: Please contact the Portnoy Law Firm to recover your losses. August 4, 2025 Deadline to file Lead Plaintiff Motion - Reckitt Benckiser Group ( OTC:RBGLY )
Investors can contact the law firm at no cost to learn more about recovering their losses
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View
THC's Q2 earnings benefit on the back of strong volumes, facility buyouts, higher acuity and favorable payer mix. It currently expects 2025 adjusted EPS within $15.55-$16.21, up from the earlier view of $11.99-$13.12.
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years
Medical device specialist DexCom ( NASDAQ: DXCM ) has encountered significant headwinds in the past year. The company's financial results haven't been quite up to the market's standards, and broader market volatility caused by President Donald Trump's trade policies isn't helping either.
All It Takes Is $2,000 Invested in Each of These High Dividend Stocks to Help Generate Over $280 in Passive Income Per Year
It has been a volatile year for the U.S. markets, with many stocks experiencing impressive highs and sharp lows. Investing in such a turbulent environment may feel daunting for retail investors.However, dividend-paying stocks can help generate substantial passive income even amid market ...
Looking Into Abbott Laboratories's Recent Short Interest - Abbott Laboratories ( NYSE:ABT )
Abbott Laboratories's ABT short percent of float has fallen 5.83% since its last report. The company recently reported that it has 19.43 million shares sold short, which is 1.13% of all regular shares that are available for trading.
Scott+Scott Attorneys at Law LLP Alerts Investors There Is an Ongoing Securities Class Action Against Reckitt Benckiser Group PLC ( OTC: RBGLY ) - Reckitt Benckiser Group ( OTC:RBGLY )
NEW YORK, July 18, 2025 ( GLOBE NEWSWIRE ) -- Scott+Scott Attorneys at Law LLP ( "Scott+Scott" ) , an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Southern District of New York against ...
Stock Market News for Jul 18, 2025
U.S. stocks ended higher on Thursday, with the S&P 500 and the Nasdaq closing at new record highs, as fresh economic data and solid earnings from a slew of big companies bolstered investors' faith in the economy.
These Analysts Revise Their Forecasts On Abbott Following Q2 Results - Abbott Laboratories ( NYSE:ABT )
Abbott Laboratories ABT reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year. The company reported second-quarter sales of $11.14 billion, beating the consensus of $11.07 billion. The U.S.
Microsoft To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Friday - Abbott Laboratories ( NYSE:ABT ) , Amphenol ( NYSE:APH )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Jefferies raised Abbott Laboratories ABT price target from $143 to $145.
Abbott Reports 12% Growth in Device Sales
Abbott Laboratories ( NYSE:ABT ) reported its second-quarter 2025 results on July 17, 2025, posting 7.5% organic sales growth ( excluding COVID testing ) , 12% medical device growth, and adjusted EPS of $1.26, an 11% increase compared to the prior year and a 16% rise compared to the first ...
P/E Ratio Insights for Abbott Laboratories - Abbott Laboratories ( NYSE:ABT )
Looking into the current session, Abbott Laboratories Inc. ABT shares are trading at $121.11, after a 8.07% drop. Over the past month, the stock fell by 8.93%, but over the past year, it actually went up by 18.71%.
Tech Breaks Record Highs: What's Moving Markets Thursday? - Grayscale Bitcoin Mini Trust ( BTC ) Common units of fractional undivided beneficial interest ( ARCA:BTC )
Nasdaq 100 hits record high above 23,000; small caps lead gains with Russell 2000 up 1.3%. June retail sales jumped 0.6%, jobless claims dropped to 221,000, signaling a resilient U.S. economy.
Abbott Reports 10.5% EPS Growth for Fiscal Q2
Abbott Laboratories ( NYSE:ABT ) , a global healthcare company known for its medical devices, diagnostics, nutrition, and pharmaceuticals, reported fiscal 2025 earnings on Thursday, July 17, that narrowly topped analysts' consensus estimates.
Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat
ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.
Abbott ( ABT ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Need a quote from one of our analysts? Email [email protected] Laboratories ( NYSE:ABT ) presented a quarter marked by distinct segment divergence, with medical devices sustaining double-digit organic sales growth and diagnostics constrained by COVID test declines ...
Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors - Abbott Laboratories ( NYSE:ABT )
Abbott's Q2 revenue hit $11.14 billion vs. $11.07 billion expected; EPS of $1.26 beat $1.25 consensus. Medical Devices sales surged 13.4% with $1.9 billion in CGM revenue, up over 21% year-over-year. Live Sunday: Matt Maley's Volatility Trading Plan for Earnings, Tariffs, & the Fed [Secure Your ...
Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Abbott Laboratories ( NYSE:ABT ) , Guess ( NYSE:GES )
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.2% on Thursday. Shares of Abbott Laboratories ABT fell sharply in pre-market trading after the company issued third-quarter adjusted EPS guidance below estimates.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis, Reckitt, and Tempus and Encourages Investors to Contact the Firm - Tempus AI ( NASDAQ:TEM ) , Reckitt Benckiser Group ( OTC:RBGLY )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vestis ( VSTS ) , Reckitt ( RBGLY ) , or Tempus ( TEM ) To Contact Him Directly To Discuss Their Options
Abbott Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Abbott Laboratories ( NYSE:ABT )
Abbott Laboratories ABT will release earnings results for the second quarter, before the opening bell on Thursday, July 17. Analysts expect the North Chicago, Illinois-based company to report quarterly earnings at $1.25 per share, up from $1.14 per share in the year-ago period.
